We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ALKS

Price
27.54
Stock movement up
+0.54 (2.00%)
Company name
Alkermes Plc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
4.46B
Ent value
4.92B
Price/Sales
2.96
Price/Book
3.45
Div yield
-
Div growth
-
Growth years
-
FCF payout
10.40%
Trailing P/E
13.37
Forward P/E
15.55
PEG
-
EPS growth
-
1 year return
10.20%
3 year return
-2.39%
5 year return
13.12%
10 year return
-7.51%
Last updated: 2025-04-14

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ALKS does not pay dividends or no data was received
The main growth driver for Alkermes going forward will be ALKS 2680. Read why I maintain my buy rating on ALKS stock.
February 25, 2025

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E13.37
Price to OCF12.52
Price to FCF14.14
Price to EBITDA12.24
EV to EBITDA13.53

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.96
Price to Book3.45
EV to Sales3.27
Alkermes plc (NASDAQ:ALKS) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ETCompany ParticipantsSandra Coombs - Senior Vice President of...
February 12, 2025

iO Charts is a Seeking Alpha partner

The following slide deck was published by Alkermes plc in conjunction with their 2024 Q4 earnings call.
February 12, 2025

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count161.80M
EPS (TTM)2.00
FCF per share (TTM)1.89

Income statement

Loading...
Income statement data
Revenue (TTM)1.51B
Gross profit (TTM)1.24B
Operating income (TTM)312.58M
Net income (TTM)333.35M
EPS (TTM)2.00
EPS (1y forward)1.77

Margins

Loading...
Margins data
Gross margin (TTM)82.31%
Operating margin (TTM)20.77%
Profit margin (TTM)22.15%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash396.29M
Net receivables370.18M
Total current assets1.56B
Goodwill83.03M
Intangible assets904.00K
Property, plant and equipment560.57M
Total assets2.16B
Accounts payable37.04M
Short/Current long term debt366.00M
Total current liabilities453.70M
Total liabilities863.18M
Shareholder's equity1.29B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)355.96M
Capital expenditures (TTM)40.74M
Free cash flow (TTM)315.22M
Dividends paid (TTM)32.77M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity25.80%
Return on Assets15.47%
Return on Invested Capital21.00%
Cash Return on Invested Capital19.86%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open27.20
Daily high27.59
Daily low27.04
Daily Volume1.76M
All-time high98.06
1y analyst estimate34.08
Beta0.43
EPS (TTM)2.00
Dividend per share-
Ex-div date-
Next earnings date29 Apr 2025

Downside potential

Loading...
Downside potential data
ALKSS&P500
Current price drop from All-time high-71.92%-12.04%
Highest price drop-96.15%-56.47%
Date of highest drop11 Jul 20029 Mar 2009
Avg drop from high-67.22%-11.07%
Avg time to new high131 days12 days
Max time to new high6317 days1805 days
Discover why Alkermes is a promising investment with strong financials and growth potential in the pharmaceutical market.
November 24, 2024

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ALKS (Alkermes Plc) company logo
Marketcap
4.46B
Marketcap category
Mid-cap
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Employees
2100
Investor relations
-
SEC filings
CEO
Richard F. Pops
Country
USA
City
Dublin D04
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ETCompany ParticipantsSandra Coombs - Senior Vice President of Investor...
October 24, 2024

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Alkermes plc (NASDAQ:ALKS) Q2 2024 Earnings Conference Call July 24, 2024 8:00 AM ETCompany ParticipantsSandra Coombs - Senior Vice President, Investor...
July 24, 2024
The following slide deck was published by Alkermes plc in conjunction with their 2024 Q2 earnings call.
July 24, 2024
The following slide deck was published by Alkermes plc in conjunction with their 2024 Q1 earnings call.
May 1, 2024
iO Charts is a Seeking Alpha partnerNext page